Related Experiment Video
Updated: Aug 15, 2026
06:08
Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay
Published on: September 22, 2023
Flavonoids as potential anti-asthmatic agents
Zhuofen Deng1, Haiyi Xin2, Dongxin Yang1
1Central Laboratory of YunFu People's Hospital, YunFu Key Laboratory of Brain Diseases Research, Guangdong Yunfu, China.
Frontiers in Immunology
|August 14, 2026
Summary
Flavonoids show promise in treating asthma by targeting inflammation and immune responses. Further clinical trials are needed to overcome bioavailability challenges for effective asthma therapy.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- Asthma impacts millions globally, with current treatments offering symptom control but no cure.
- Existing asthma pharmacotherapies have systemic side effects and do not address underlying pathologies.
- Flavonoids possess diverse biological activities, yet their mechanisms in asthma require comprehensive review.
Purpose of the Study:
- To review the mechanisms by which flavonoids modulate key asthma pathologies.
- To summarize evidence on flavonoids' effects on airway inflammation, T cell imbalance, airway remodeling, and smooth muscle contractility.
- To assess the clinical translatability of flavonoid-based asthma therapies.
Main Methods:
- Systematic review of preclinical and clinical studies on flavonoids and asthma.
- Analysis of flavonoid interactions with cellular and molecular pathways involved in asthma.
- Evaluation of pharmacokinetic and pharmacodynamic properties of flavonoids relevant to asthma treatment.
Main Results:
- Flavonoids demonstrate multi-target potential by influencing airway inflammation and T cell subsets.
- Evidence suggests flavonoids can modulate airway remodeling and smooth muscle hyperresponsiveness.
- Significant challenges exist for clinical application, including poor solubility and bioavailability.
Conclusions:
- Flavonoids offer a promising therapeutic avenue for asthma due to their multi-target actions.
- Overcoming pharmacokinetic limitations is crucial for realizing the clinical potential of flavonoids in asthma.
- Large-scale, well-designed clinical trials are essential to validate flavonoid efficacy for asthma management.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:24Antiasthma Drugs: Methylxanthines
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...